CoChat

Tumor-educated mesenchymal stem cells promote pro-metastatic phenotype

Open access
Hill, Billy Samuel, Pelagalli, Alessandra, Passaro, Nunzia, Zannetti, Antonella · 2017 · Oncotarget
Cited by 104

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

// Billy Samuel Hill 1, * , Alessandra Pelagalli 1, 2, * , Nunzia Passaro 1 and Antonella Zannetti 1 1 Institute of Biostructures and Bioimaging (IBB), National Research Council (CNR), Naples, Italy 2 Department of Advanced Biomedical Sciences, University of Naples “Federico II”, Naples, Italy * Authors contributed equally to this work Correspondence to: Antonella Zannetti, email: antonella.zannetti@cnr.it Keywords: mesenchymal stem cells, tumor microenvironment, epithelial-mesenchymal transition, metastatic phenotype Received: February 03, 2017 Accepted: August 04, 2017 Published: August 14, 2017 ABSTRACT Multipotent mesenchymal stem cells (MSCs) are recruited into tumor microenvironment in response to multiple signals produced by cancer cells. Molecules involved in their homing to tumors are the same inflammatory mediators produced by injured tissues: chemokines, cytokines and growth factors. When MSCs arrive into the tumor microenvironment these are “educated” to have pro-metastatic behaviour. Firstly, they promote cancer immunosuppression modulating both innate and adaptive immune systems. Moreover, tumor associated-MSCs trans-differentiating into cancer-associated fibroblasts can induce epithelial-mesenchymal-transition program in tumor cells. This process determinates a more aggressive phenotype of cancer cells by increasing their motility and invasiveness and favoring their dissemination to distant sites. In addition, MSCs are involved in the formation and modelling of pre-metastatic niches creating a supportive environment for colonization of circulating tumor cells. The development of novel therapeutic approaches targeting the different functions of MSCs in promoting tumor progression as well as the mechanisms underlying their activities could enhance the efficacy of conventional and immune anti-cancer therapies. Furthermore, many studies report the use of MSCs engineered to express different genes or as vehicle to specifically deliver novel drugs to tumors exploiting their strong tropism. Importantly, this approach can enhance local therapeutic efficacy and reduce the risk of systemic side effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.20265

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

Metadata

Authors
Hill, B. S., Pelagalli, A., Passaro, N., & Zannetti, A.
Venue
Oncotarget
Published
2017-08-14
Volume
8
Issue
42
Pages
73296-73311
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2746059023
Cited by
104
References
28
FWCI
6.56
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.